Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02499861
Recruitment Status : Completed
First Posted : July 16, 2015
Last Update Posted : November 17, 2017
Information provided by (Responsible Party):
Henrique Bittencourt, MD, PhD, St. Justine's Hospital

Brief Summary:

This Phase I/IIa study will test the combination of the epigenetic drug decitabine with the isoflavone genistein in children with leukemias and solid tumors. For the phase I study, the maximum tolerated dose will be evaluated in pediatric patients with relapsed or refractory leukemia and solid tumors. For the phase II study, only patients with relapsed or refractory leukemias will be included. To further evaluate the treatment efficacy and gain further insight into action of these drugs, the DNA methylation levels before and after treatment for all participants, pharmacokinetics parameters such as through level for decitabine and through and peak level for genistein will be measured. Pharmacogenomics testing for decitabine will be performed prior to cycle 1 of treatment.

Decitabine will be administered over a 24 hours infusion on day 1 of cycle (28 days) and genistein will be taken orally twice daily from day 2 to 21, followed by a 7 days rest period.

Condition or disease Intervention/treatment Phase
Cancer Drug: Decitabine and Genistein Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/IIa Study of Decitabine in Combination With Genistein in Pediatric Patients With Relapsed or Refractory Solid Tumors and Leukemia
Study Start Date : July 2015
Actual Primary Completion Date : October 24, 2017
Actual Study Completion Date : October 24, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia

Arm Intervention/treatment
Experimental: Decitabine and Genistein
continuous 24 hours Intravenous decitabine followed by oral genistein for 20 days.
Drug: Decitabine and Genistein
intravenous Decitabine with oral genistein

Primary Outcome Measures :
  1. Maximum tolerated dose of the combination of intravenous decitabine with oral genistein for children with refractory or recurrent solid malignancies and leukemia [ Time Frame: 12-18 mnths ]
  2. Number of participants with adverse events as a measurement of safety and tolerability of the combination of intravenous decitabine with oral genistein in children. [ Time Frame: 12-18 months ]
  3. Clinical benefit of the combination of intravenous decitabine with oral genistein in phase IIa of the study measure by either volumetric MRI for solid tumor or by bone marrow aspiration or biopsy for leukemia) at the end of cycle 2, 4, 6, 9 and 12. [ Time Frame: 42 months ]

Secondary Outcome Measures :
  1. Plasma concentration of decitabine and genistein during cycle 1 and 2 (just in Phase I). [ Time Frame: 12-18 months ]
  2. DNA methylation levels in selected gene promoters before and after treatment. [ Time Frame: 42 months ]
  3. Quality of life assess through Peds Quality of Life Cancer module, Peds Quality of Life Fatigue module, Reported Health status 15-items, Pain Visual Analogue Scale, Distress Rating Scale, Expectations and McGill Quality of Life Questionnaire [ Time Frame: 42 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age ≥ 2 years of age and < 21 years of age at time of study enrollment
  • Able to swallow genistein or take it with a puree.
  • Patients must have a diagnosis of recurrent or refractory solid tumors, including Central Nervous System tumors, lymphoma or leukemia for which standard curative measures do not exist or are no longer effective
  • For solid tumors, patients must have either measurable or evaluable disease. For leukemia, patients must have > 5% blasts in the bone marrow.
  • Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy.
  • Performance level: Karnofsky ≥50% for patients ≥ 16 years of age or Lansky ≥ 50% for patients < 16 years of age
  • Life expectancy at least one month
  • Patients must have adequate bone-marrow function
  • Patients must have normal organ as defined below: (total bilirubin ≤ 24microM/L), Amylase/pancreatic amylase≤1.5 × institutional upper limit of normal, Aspartate Aminotransferase (AST) /Alanine Aminotransferase (ALT) ≤2.5 × institutional upper limit of normal, creatinine clearance ≥60 mL/min/1.73 m2.

OR creatinine according to age/gender

  • Nervous system disorders (CTCAE v4) resulting from prior therapy must be ≤ Grade 2
  • Participants of child-bearing potential and men must agree to use adequate contraception for the duration of study treatment, and 4 months after completion of decitabine and genistein administration.
  • All patients and/or their parents or legally authorized representatives must sign a written informed consent

Exclusion Criteria:

  • Prior decitabine or genistein therapy.
  • Patients who are receiving any other investigational agents.
  • Nasogastric or gastrostomy (or equivalent) administration of genistein is not allowed.
  • Patients with known exclusive non-measurable leptomeningeal disease at enrolment should be excluded from this clinical trial.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine and genistein.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (receiving antibiotics), symptomatic heart or lung disease, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant or breast-feeding women are excluded from this study. All girls of child bearing potential must have a negative pregnant test prior to enrolment.
  • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02499861

Layout table for location information
Canada, Quebec
St. Justine's Hospital
Montreal, Quebec, Canada, H3T 1C5
Sponsors and Collaborators
St. Justine's Hospital
Layout table for investigator information
Principal Investigator: Henrique Bittencourt, MD St. Justine's Hospital

Layout table for additonal information
Responsible Party: Henrique Bittencourt, MD, PhD, Pediatric Hematologist-Oncologist, St. Justine's Hospital Identifier: NCT02499861    
Other Study ID Numbers: DEC-GEN001
First Posted: July 16, 2015    Key Record Dates
Last Update Posted: November 17, 2017
Last Verified: November 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Protein Kinase Inhibitors
Estrogens, Non-Steroidal
Hormones, Hormone Substitutes, and Hormone Antagonists